Seminars in Thoracic and Cardiovascular Surgery
Volume 19, Issue 2 , Pages 142-150 , Summer 2007

Medical Therapy for Chronic Obstructive Pulmonary Disease in 2007

  • Edward P. Ingenito, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Edward P. Ingenito, MD, PhD, Pulmonary/Critical Care Division, Department of Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115.

References 

  1. Anzueto A. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions. Am J Med. 2006;119(suppl 1):46–53
  2. Hnizdo E, Glindmeyer HW, Petsonk EL, et al. Case definitions for chronic obstructive pulmonary disease. COPD. 2006;3:95–100
  3. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med. 2006;173:985–990
  4. Lacoste JY, Bousquet J, Chanez P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92:537–548
  5. Mueller R, Chanez P, Campbell AM, et al. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med. 1996;90:79–85
  6. Rennard SI. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:S12–S16
  7. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest. 2002;121(suppl):151S–155S
  8. Maestrelli P, di Stefano A, Occari P, et al. Cytokines in the airway mucosa of subjects with asthma induced by toluene diisocyanate. Am J Respir Crit Care Med. 1995;151:607–612
  9. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med. 1995;152:1926–1931
  10. Saetta M, Baraldo S, Zuin R. Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease: fatal chemo-attraction?. Am J Respir Crit Care Med. 2003;168:911–913
  11. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994;150:1646–1652
  12. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822–826
  13. Mills PR, Davies RJ, Devalia JL. Airway epithelial cells, cytokines, and pollutants. Am J Respir Crit Care Med. 1999;160:S38–S43
  14. Capelli A, Di Stefano A, Gnemmi I, et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J. 1999;14:160–165
  15. Vignola AM, Chanez P, Chiappara G, et al. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am J Respir Crit Care Med. 1997;156:591–599
  16. de Boer WI, van Schadewijk A, Sont JK, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1951–1957
  17. Cohen AB, Chenoweth DE, Hugli TE. The release of elastase, myeloperoxidase, and lysozyme from human alveolar macrophages. Am Rev Respir Dis. 1982;126:241–247
  18. Cohen AB, James HL. Reduction of the elastase inhibitory capacity of alpha 1-antitrypsin by peroxides in cigarette smoke: an analysis of brands and filters. Am Rev Respir Dis. 1982;126:25–30
  19. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes (Potential roles in destructive lung disease). Am J Respir Crit Care Med. 1994;150:S160–S164
  20. Witko-Sarsat V, Cramer EM, Hieblot C, et al. Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules. Blood. 1999;94:2487–2496
  21. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol. 1999;20:729–736
  22. Witko-Sarsat V, Lesavre P, Lopez S, et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J Am Soc Nephrol. 1999;10:1224–1233
  23. Pierson DJ. Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respir Care. 2006;51:277–288
  24. Fabbri L, Pauwels RA, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD. 2004;1:105–141discussion 103-104
  25. Pauwels RA, Buist AS, Ma P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46:798–825
  26. Roth MD, Connett JE, D’Armiento JM, et al. Feasibility of retinoids for the treatment of emphysema study. Chest. 2006;130:1334–1345
  27. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc. 2005;2:272–281discussion 290-291
  28. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone (An 85-day multicenter trial). Chest. 1994;105:1411–1419
  29. Ikeda A, Nishimura K, Koyama H, et al. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest. 1995;107:401–405
  30. Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290:2301–2312
  31. Cazzola M, Di Perna F, Centanni S, et al. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax. 1999;54:1083–1086
  32. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004;98:1214–1221
  33. Cazzola M, Noschese P, Salzillo A, et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. 2005;99:524–528
  34. Ram FS, Jardin JR, Atallah A, et al. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med. 2005;99:135–144
  35. Filuk RB, Easton PA, Anthonisen NR. Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;132:871–874
  36. Tsukino M, Nishimura K, Ikeda A, et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax. 1998;53:269–273
  37. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:1661–1670
  38. Masubuchi T, Koyama S, Sato E, et al. Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Pathol. 1998;153:1903–1912
  39. Adcock IM, Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc. 2005;2:313–319discussion 340-341
  40. Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD. 2005;2:445–455
  41. Spencer S, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698–702
  42. Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:1958–1964
  43. Postma DS, Steenhuis EJ, van der Weele LT, et al. Severe chronic airflow obstruction: can corticosteroids slow down progression?. Eur J Respir Dis. 1985;67:56–64
  44. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking (European Respiratory Society Study on Chronic Obstructive Pulmonary Disease). N Engl J Med. 1999;340:1948–1953
  45. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–1823
  46. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303
  47. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456
  48. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834–843
  49. Nannini L, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;3:CD003794
  50. Li HT, Zhang TT, Zhou H, et al. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. Respiration. 2007;74:33–43
  51. Mapel DW, Nelson LS, Lydick E, et al. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD. 2007;4:127–134
  52. Naya IP, Andersson TL. Post hoc analysis and claims of superiority in the EXCEL trial. Respir Med. 2007;101:681–682author reply 683
  53. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157:351–370
  54. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2001;10:1361–1379
  55. Pulmonary-Allergy drug products advisory committee, Center for Drug Evaluation and Research, FDA, Department of Health and Human Services, SB 207499 (Cilomilast), GlaxoSmithKline. New Drugs Application (21-573), 2005
  56. Losco PE, Evans EW, Barat SA, et al. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol. 2004;32:295–308
  57. American Thoracic Society—pulmonary rehabilitation. Am J Respir Crit Care Med. 1999;159:1666–1682
  58. Pulmonary Rehabilitation: joint ACCP/AACVPR evidence based guidelines. ACCP/ACCVPR pulmonary rehabilitation guidelines panel, American College of Chest Physicians, American Association of Cardiovascular and Pulmonary Rehabilitation. Chest. 1997;112:1363–1396
  59. Berry MJ, Rejeski WJ, Adair NE, et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med. 1999;160:1248–1253
  60. Weiner P, Magadle R, Beckerman M, et al. Maintenance of inspiratory muscle training in COPD patients: one year follow-up. Eur Respir J. 2004;23:61–65
  61. Na JO, Kim DS, Yoon SH, et al. A simple and easy home-based pulmonary rehabilitation programme for patients with chronic lung diseases. Monaldi Arch Chest Dis. 2005;63:30–36
  62. Wijkstra PJ, Van Altena R, Kraan J, et al. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J. 1994;7:269–273
  63. Cockram J, Cecins N, Jenkins S. Maintaining exercise capacity and quality of life following pulmonary rehabilitation. Respirology. 2006;11:98–104
  64. Maltais F, Bourbeau J, Lacasse Y, et al. A Canadian, multicentre, randomized clinical trial of home-based pulmonary rehabilitation in chronic obstructive pulmonary disease: rationale and methods. Can Respir J. 2005;12:193–198
  65. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–1413
  66. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease–2003. Can Respir J. 2003;10(Suppl A):11A–65A
  67. O’Donnell DE, Aaron S, Bourbeau J, et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J. 2004;11(Suppl B):7B–59B
  68. Nocturnal Oxygen Therapy Trail Group. Continuous or nocturnal oxygen therapy in chronic hypoxemic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93:391–398
  69. Report of the Medical Research Council Working Party (Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema). Lancet. 1981;1:681–686
  70. Crockett AJ, Cranston JM, Moss JR, et al. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Intern Med J. 2001;31:448–454
  71. Crockett AJ, Cranston JM, Moss JR, et al. A review of long-term oxygen therapy for chronic obstructive pulmonary disease. Respir Med. 2001;95:437–443
  72. Cullen DL. Long term oxygen therapy adherence and COPD: what we don’t know. Chronic Respir Dis. 2006;3:217–222
  73. Nonoyama ML, Brooks D, Guyatt GH, et al. Effect of oxygen on health quality of life in COPD patients with transient exertional hypoxemia. Am J Respir Crit Care Med. 2007;Apr 19 [epub ahead of print]
  74. Nonoyama M, Brooks D, Lacasse Y, et al. Oxygen therapy during exercise training in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;2:CD005372
  75. Eaton T, Fergusson W, Kolbe J, et al. Short-burst oxygen therapy for COPD patients: a 6-month randomised, controlled study. Eur Respir J. 2006;27:697–704
  76. Quantrill SJ, White R, Crawford A, et al. Effect of short burst oxygen therapy after activities of daily living in the home in chronic obstructive pulmonary disease. Thorax. 2007;Feb 20 [epub ahead of print]
  77. Kozora E, Filley CM, Julian LJ, et al. Cognitive functioning in patients with chronic obstructive pulmonary disease and mild hypoxemia compared with patients with mild Alzheimer disease and normal controls. Neuropsychiatry Neuropsychol Behav Neurol. 1999;12:178–183
  78. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648
  79. Geddes D, Davies M, Koyama H, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med. 2000;343:239–245
  80. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369–390
  81. Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions (Health Educational Authority). Thorax. 1998;53(suppl 5):S1–S38
  82. Lancaster T, Stead L, Silagy C, et al. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ. 2000;321:355–358
  83. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2000;2:CD001292
  84. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2000;2:CD001118
  85. Kottke TE, Battista RN, DeFriese GH, et al. Attributes of successful smoking cessation interventions in medical practice (A meta-analysis of 39 controlled trials). JAMA. 1988;259:2883–2889
  86. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691
  87. Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs. 2006;21:433–436
  88. Williams KE, Reeves KR, Billing CB, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23:793–801
  89. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol. 1996;270:L305–L310
  90. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997;3:675–677

PII: S1043-0679(07)00090-1

doi: 10.1053/j.semtcvs.2007.06.003

Seminars in Thoracic and Cardiovascular Surgery
Volume 19, Issue 2 , Pages 142-150 , Summer 2007

Article Tools